2024
Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). Blood 2024, 144: 3378-3378. DOI: 10.1182/blood-2024-208341.Peer-Reviewed Original ResearchMedian time to responseRelapsed AL amyloidosisTime to responseAL amyloidosisPartial responseHematologic responseComplete responseCardiac involvementOverall survivalRenal involvementOrgan involvementEastern Cooperative Oncology Group performance statusRate of hematologic responseAutologous stem cell transplantationProspective phase II trialLight chain (AL) amyloidosisDistribution of organ involvementProgression free survivalHematologic complete responseHematologic response rateStem cell transplantationPhase II trialAnti-CD38 antibodiesSystemic AL amyloidosisRate of patients
2009
Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.Peer-Reviewed Original ResearchConceptsWaldenstrom's macroglobulinemiaLymphoplasmacytic cellsClonal lymphoplasmacytic cellsHigh-dose chemotherapyBone marrow infiltrationInternational Staging SystemStem cell transplantationB-cell disordersComplete remissionFrontline therapyObjective responseMarrow infiltrationCell transplantationStaging systemTherapeutic armamentariumMonoclonal gammopathyNovel agentsMacroglobulinemiaTherapyProteasome inhibitorsDisease biologyNucleoside analoguesPromising activityRecent studiesRecent advances